CoChat
Sign Up
Cited by 50

The DOI matches its Crossref record.

Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients

Gaude, GajananS, Chaudhury, Alisha, Hattiholi, Jyothi·2015·Journal of Family Medicine and Primary Care
DOI 10.4103/2249-4863.154661PMC PMC4408708
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4103/2249-4863.154661

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 24

  1. [1]Parthasarathy R Sarma GR Janardhanam B Ramachandran P Santha T Sivasubramanian S Hepatic toxicity in south Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide Tubercle 1986 67 99 108 3775870
  2. [2]Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampicin, and pyrazinamide in a controlled trial of three 6- month regimens for smear-positive pulmonary tuberculosis Am Rev Respir Dis 1991 143 707 12 1901200
  3. [3]Myesr JP New recommendations for the treatment of tuberculosis Curr Opin Infect Dis 2005 18 133 40 15735417
  4. [4]Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six month and four month regimens of chemotherapy in the treatment of pulmonary tuberculosis: The results up to 30 months Tubercle 1981 62 95 102 7029838
  5. [5]Sharma SK Balamurugan A Saha PK Pandey RM Mehra NK Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment Am J Respir Crit Care Med 2002 166 916 9 12359646
  6. [6]Tost JR Vidal R Caylà J Díaz-Cabanela D Jiménez A Broquetas JM Severe hepatotoxicity due to anti-tuberculosis drugs in Spain Int J Tuberc Lung Dis 2005 9 534 40 15875925
  7. [7]Thompson NP Caplin ME Hamilton MI Gillepsie SH Clarke SW Burrough AK Anti-tuberculosis medication and the liver: Dangers and recommendations in management Eur Respir J 1995 1384 8 7489806
  8. [8]Gangadharan PR Isoniazid, rifampicin and hepatotoxicity Am Rev Respir Dis 1986 133 963 5 3013057
  9. [10]Hassen Ali A Belachew T Yami A Ayen WY Anti-Tuberculosis Drug Induced Hepatotoxicity among TB/HIV Co-Infected Patients at Jimma University Hospital, Ethiopia: Nested Case-Control Study PLoS ONE 2013 8 e64622 23696901 PMC3655990
  10. [11]Saukkonen JL Cohn DL Jasmer RM Schenker S Jereb JA Nolan CM An official ATS statement: Hepatotoxicity of antituberculosis therapy Am J Respir Crit Care Med 2006 174 935 52 17021358
  11. [12]Steele MA Burk RF DesPrez RM Toxic hepatitis with isoniazid and rifampin. A meta-analysis Chest 1991 99 465 71 1824929
  12. [13]Chang KC Leung CC Yew WW Lau TY Tam CM Tuberculosis and chest service, centre for health hepatotoxicity of pyrazinamide cohort and case-control analyses Am J Respir Crit Care Med 2008 177 1391 6 18388355
  13. [14]Kato H Horita N Miyazawa N Yoshiyama T Ueda A Ishigatsubo Y Risk factors for liver injury with an elevated serum bilirubin concentration caused by antituberculous drugs Intern Med 2013 52 2209 14 24088753
  14. [15]Babalik A Arda H Bakirci N Agca S Oruc K Kiziltas Ş Management of and risk factors related to hepatotoxicity during tuberculosis treatment Tuberk Toraks 2012 60 136 44 22779934
  15. [16]Pande JN Singh SP Khilnani GC Khilnani S Tandon RK Risk factors for hepatotoxicity from antituberculosis drugs: A case-control study Thorax 1996 51 132 6 8711642 PMC473016
  16. [17]Grönhagen-Riska C Hellstrom PE Froseth B Predisposing factors in hepatitis induced by isoniazid-rifampicin treatment of tuberculosis Am Rev Respir Dis 1978 118 461 6 707874
  17. [18]Mehta S Malnutrition and drugs: Clinical implications Dev Pharmacol Ther 1990 15 159 65 2129200
  18. [19]Mo P Zhu Q Teter C Yang R Deng L Yan Y Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus Int J Infect Dis 2014 28 95 100 25218771
  19. [20]Riaska N Hepatitis cases in isoniazid treated groups and in a control group Bull Int Union Tuberc 1976 51 203 6 1030282
  20. [21]Teleman MD Chee CB Earnest A Wang YT Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore Int J Tuberc Lung Dis 2002 6 699 705 12150482
  21. [22]Gurumurthy P Krisnamurthy MS Nazareth O Parthasarthy R Sarma GR Somasundaran PR Lack of relationship between hepatic toxicity and acetylator phenotypes in 3000 south Indian patients during treatment with isoniazid for tuberculosis Am Rev Respir Dis 1984 129 58 61 6367570
  22. [23]Kumar A Misra PK Mehrotra R Govil YC Rana GS Hepatotoxicity of rifampicin and isoniazid: Is it all drug induced hepatitis? Am Rev Respir Dis 1991 143 1350 2 1904700
  23. [26]Tahaoğlu K Ataç G Sevim T Tärün T Yazicioğlu O Horzum G The management of anti-tuberculosis drug-induced hepatotoxicity Int J Tuberc Lung Dis 2001 5 65 9 11263519
  24. [27]Devarbhavi H Anti-tuberculous drug-induced liver injury: Current perspective Trop Gastroenterol 2011 32 167 74 22332331

Cited by

Sorted by citations

Metadata

Authors
Gaude, G., Chaudhury, A., & Hattiholi, J.
Venue
Journal of Family Medicine and Primary Care
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2015
Volume
4
Issue
2
Pages
238
ISSN
2249-4863
DOI
10.4103/2249-4863.154661
PMC
PMC4408708
Cited by
50
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review